ArriVent Biopharma, a Newtown Square, PA-based company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, raised $155M in Series B funding.
The round was led by Sofinnova Investments and General Catalyst, with participation from Catalio Capital Management, HBM Healthcare Investments, Shanghai Healthcare Capital, Sequoia China, AIHC Capital, Terra Magnum Capital Partners, Unicorn Capital Partners Limited, Infinitum Asset Management, Lilly Asia Ventures, OrbiMed, Octagon Capital Advisors, Sirona Capital, and Boyu/Zoo Capital. In conjunction with the funding, Jim Healy, Sofinnova Investments, and Carl Gordon, OrbiMed Advisors, will be joining ArriVent’s board of directors.
The company intends to use the funds to support pivotal Phase 3 and additional studies of lead product candidate, furmonertinib, as well as future pipeline expansion.
Led by CEO Bing Yao, ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products. Its lead product candidate, furmonertinib, is a highly brain penetrant, mutant-specific EGFR kinase inhibitor.
With a deep and global network, the company seeks to access drug candidates at various development stages, including those coming from China and other emerging biotech hubs. Through strategic collaborations with innovative biopharma companies, ArriVent aims to globalize medicines for patients with unmet medical need in a broad range of diseases, with an initial focus in oncology.
